Our strategy is to leverage our gene regulation technology to maximize value. To achieve this goal, we are pursuing the following milestones.

• Develop therapeutic topical products for humans and animals. Upon successful completion of Phase I/II of clinical trials, the company intends to seek licensing agreements with domestic and foreign pharmaceutical companies. These agreements will fund the remaining clinical trials and FDA marketing approval steps.
• Generate revenue by providing Drug Target Validation services while seeking and forming product development partnerships with pharmaceutical and biotechnology companies.
• Develop a cGMP manufacturing facility to produce DNA drug substance for CytoGenix products in development. Additional capacity will be utilized for the manufacturing campaigns on a fee-for-service basis.

Our patented technology represents a significant breakthrough in intra-cellular gene regulation; and our topical preparations demonstrate a high safety/efficacy profile. Our novel cell-free production capability of clinical grade DNA represents a major advance in the field and has positioned CytoGenix to become a leader in this cutting edge area of therapeutic development.

For this reason, we are pursuing product opportunities meeting these criteria:

• Diseases and disorders of the skin and others amenable to topical formulation drug delivery through body orifices (ocular, nasal, vaginal and anal) and,
• Diseases for which current drugs and those in late trials are not very effective and,
• Diseases with high incidence rates, global markets and significant unmet medical need.

Published laboratory (in vitro) studies have shown very clearly that the Company's gene regulation technology is highly effective in reducing protein expression in target cells. These scientific results have led to the execution of a product development strategy directed toward skin diseases and conditions treatable via topical delivery.